GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (STU:CZTA) » Definitions » Additional Paid-In Capital

Checkpoint Therapeutics (STU:CZTA) Additional Paid-In Capital : €286.68 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics Additional Paid-In Capital?


Checkpoint Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 (€258.76 Mil) to Dec. 2023 (€273.14 Mil) and increased from Dec. 2023 (€273.14 Mil) to Mar. 2024 (€286.68 Mil).

Checkpoint Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€197.36 Mil) to Dec. 2022 (€227.61 Mil) and increased from Dec. 2022 (€227.61 Mil) to Dec. 2023 (€273.14 Mil).

Checkpoint Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Checkpoint Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Additional Paid-In Capital Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 122.80 142.98 197.36 227.61 273.14

Checkpoint Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.23 245.71 258.76 273.14 286.68

Checkpoint Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Checkpoint Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics (STU:CZTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (STU:CZTA) » Definitions » Additional Paid-In Capital
Comparable Companies
DARE BYSI KA CELU SLDB YS GDTC QNCX SRNEQ INTS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CKPT:USA
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Website
https://www.checkpointtx.com
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Checkpoint Therapeutics (STU:CZTA) Headlines

No Headlines